Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canopy-A: Canakinumab in adjuvant NSCLC
NCT03447769Phase 3Terminated
- Sponsor
- Novartis
- Start
- Mar 2018
- Primary completion
- Mar 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 41
01
Overview
A Phase 3 trial of canakinumab in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Mar 2018; status: terminated.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03447769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03447769.